Health; Destination 3: Tackling diseases and reducing disease burden.
Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs
Scope: Immunotherapy is defined as a treatment able to stimulate or restore the ability of the immune (defence) system to fight infection, disease or disorder. It has proved to be a valuable medical treatment notably when preventive interventions are not available. Passive and active immunotherapies (such as antibody-based, RNA-based and cell-based therapies, respectively) are covered by this topic, which is aiming at the pre-clinical to first-in human development of next generation immunotherapies for unmet needs.
Preclinical development and study of new immunotherapeutic agents in vitro and in relevant animal model(s) of the disease(s). This includes understanding of the therapy’s agent(s) mode of action, its toxicity, the development of related potency assay(s), and its/their validation in vitro and in vivo.
Project budget: 6M (Total budget 60M); Deadline: 1 February 2022 (1st stage), 6 September 2022 (2nd stage). More
